NLRP3 and amyotrophic lateral sclerosis: An NLRP3 inhibitor, such as MCC950, that is known to block IL-1β induction, could be purposed to unravel the effects of mitochondrial permeability transition and both major deficits on motor function in SOD1-ALS models.